Literature DB >> 462574

Clinical data and estradiol receptor evaluation in breast cancer biopsies.

G Di Fronzo, A Bertuzzi, R Saccozzi.   

Abstract

To determine the correlation between the response to the estradiol receptor test and some fundamental properties of the tumor and the host, a study was conducted on 337 patients. Primary carcinomas, including lobular carcinomas, and recurrences or metastases are characterized by similar frequencies of response to the estradiol receptor test (68% positive, 26% negative and 6% borderline), while normal breast tissue is characterized by a higher frequency of negative results (3% positive, 71% negative and 26% borderline). Postmenopausal patients show a shift of estradiol receptor levels towards higher values with respect to premenopausal patients. Contemporaneously, an increase in estradiol receptor concentrations with patient age is observed. The clinical stage appears in influence estradiol receptor content only in postmenopausal patients, for whom an increase in the tumor size is accompanied by a decrease in the estradiol receptor levels. The apparent association constant of the receptors assumes values ranging from 1.5 to about 300 X 10(9) M-1 and does not appear to be related to either the type of tumor tissue or to the clinical stage of the tumor, age, or menopausal status of the patients.

Entities:  

Keywords:  Age Factors; Biology; Breast Cancer; Cancer; Correlation Studies; Demographic Factors; Diseases; Endocrine System; Estrogens; Hormone Receptors--analysis; Hormones; Membrane Proteins; Menopause; Neoplasms; Physiology; Population; Population Characteristics; Reproduction; Research Methodology; Statistical Studies; Studies

Mesh:

Substances:

Year:  1979        PMID: 462574     DOI: 10.1177/030089167906500211

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer.

Authors:  A Bertuzzi; M G Daidone; G Di Fronzo; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.